Lucie Turcotte, MD, MPH, MS
Director, Survivorship Program
United States
Administrative support contact: Elizabeth Hendrickson Nalli
Dr. Lucie Turcotte is an Associate Professor of Pediatrics in the Division of Hematology/Oncology at the University of Minnesota. She received her MPH in Maternal and Child Health from the University of Minnesota School of Public Health in 2005, her medical degree from the University of Minnesota Medical School in 2007, and her MS in Clinical Research from the University of Minnesota School of Public Health in 2015. Dr. Turcotte completed her residency in Pediatrics in 2010 at Seattle Children's Hospital (University of Washington) in Seattle, WA, and completed her fellowship in Pediatric Hematology, Oncology, and Bone Marrow Transplant in 2013 at the University of Minnesota Masonic Children's Hospital. Dr. Turcotte's research has focused on second malignancies and short- and long-term outcomes in pediatric cancer survivors. She has specific clinical interest in childhood leukemias and lymphomas, as well as in histiocytic disorders.
Awards & Recognitions
- Minneapolis - St. Paul “Top Doctors”
- Minneapolis - St. Paul Magazine (2016-2022, 2024); Minnesota Monthly “Top Doctors”
- Minnesota Monthly Magazine; Associate or Full Professor Clinical/Translational Paper of the Year, Department of Pediatrics, University of Minnesota (2024);
Education
MPH in Maternal and Child Health, University of Minnesota School of Public Health, Minneapolis, MN
MS in Clinical Research, University of Minnesota School of Public Health, Minneapolis, MN
MD at the University of Minnesota Medical School, Minneapolis, MN
Residency in Pediatrics at the University of Washington/Seattle Children’s Hospital, Seattle, Washington, United States
Fellowship in Pediatric Hematology/Oncology, BMT at the University of Minnesota Medical School, Minneapolis, Minnesota, United States
Research
Dr. Turcotte’s research is primarily focused on short- and long-term outcomes of cancer and hematopoietic cell transplantation therapies, and on understanding the biologic underpinnings of cancer etiology and treatment response. She leads the Second Malignancy Working Group within the Childhood Cancer Survivor Study and is the Silo Leader for the Subsequent Malignant Neoplasm and Cancer Screening Task Force for the Children’s Oncology Group Long-Term Follow-Up Guidelines. Dr. Turcotte has received institutional, foundation, and federal funding to investigate novel topics in cancer survivorship with the overarching goal of enhancing the quantity and quality of life among survivors.
Clinical
Clinical Interests: Leukemia, lymphoma, histiocyte disorders